<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Ipratropium" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Ipratropium</book-part-id>
      <title-group>
        <title>Ipratropium</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>7</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Ipilimumab" document-type="chapter">Ipilimumab</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Irbesartan" document-type="chapter">Irbesartan</related-object>
    </book-part-meta>
    <body>
      <sec id="Ipratropium.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Ipratropium.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Ipratropium is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis and emphysema. Ipratropium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Ipratropium.Background">
          <title>Background</title>
          <p>Ipratropium (ip" ra troe' pee um) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing bronchial smooth muscle contractions and alleviating bronchospasm in patients with chronic obstructive pulmonary disease (COPD). Ipratropium has potent activity against muscarinic acetylcholine type 3 (M3) receptors which are found in bronchial smooth muscle. Its quaternary ammonium structure decreases its ability to cross lipid membranes such as the blood brain barrier. Ipratropium was approved for use in the United States in 1986 as a respiratory inhalant and indications include maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema. Ipratropium is available in various formulations generically and under the brand names Atrovent and Combivent for use as an inhalant. The typical dose in adults is 1 inhalation 3 to 4 times daily. The common side effects of parasympathetic stimulation (such as dryness of the mouth and eyes, decreased sweating, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety and restlessness) are uncommon in patients treated with ipratropium by inhaler. Ipratropium use can cause paradoxical bronchospasm. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.</p>
        </sec>
        <sec id="Ipratropium.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Like other anticholinergic agents, ipratropium has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to its low systemic absorption when administered by inhaler.</p>
          <p>References on the safety and potential hepatotoxicity of anticholinergics are given together after the Overview section on Anticholinergic Agents.</p>
          <p>Drug Class: <related-object source-id="livertox" document-id="Anticholinergics">Anticholinergic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Ipratropium.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <boxed-text position="anchor" id="Ipratropium.BPI" orientation="portrait">
          <p>
            <bold>REPRESENTATIVE TRADE NAMES</bold>
          </p>
          <p>Ipratropium &#x02013; Generic, Atrovent&#x000ae;</p>
          <p>
            <bold>DRUG CLASS</bold>
          </p>
          <p>Anticholinergic Agents</p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Ipratropium">COMPLETE LABELING</ext-link>
          </p>
          <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
        </boxed-text>
      </sec>
      <sec id="Ipratropium.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Ipratropium.T1" position="anchor" orientation="portrait">
          <table>
            <thead>
              <tr>
                <th id="hd_h_Ipratropium.T1_1_1_1_1" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Ipratropium.T1_1_1_1_2" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Ipratropium.T1_1_1_1_3" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Ipratropium.T1_1_1_1_4" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Ipratropium.T1_1_1_1_1" rowspan="1" colspan="1">Ipratropium</td>
                <td headers="hd_h_Ipratropium.T1_1_1_1_2" rowspan="1" colspan="1">66985-17-9</td>
                <td headers="hd_h_Ipratropium.T1_1_1_1_3" rowspan="1" colspan="1">C20-H30-Br-N-O3.x-H2-O</td>
                <td headers="hd_h_Ipratropium.T1_1_1_1_4" rowspan="1" colspan="1">
                  <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Ipratropium_Structure.jpg" mime-subtype="jpeg" position="anchor" orientation="portrait">
                    <alt-text>Ipratropium Chemical Structure</alt-text>
                  </graphic>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Ipratropium.OTHER_REFERENCE_LINKS" sec-type="link-group">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Ipratropium/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)">Recent References on Ipratropium: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Ipratropium">Trials on Ipratropium: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
